Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (2015-2025)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Phân tích ảnh hưởng
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's disease
Tập 4 Số 1 - Trang 575-590 - 2018
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro...
Alzheimer's disease drug development pipeline: 2018
Tập 4 Số 1 - Trang 195-214 - 2018
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in...
Alzheimer's disease drug development pipeline: 2017
Tập 3 Số 3 - Trang 367-384 - 2017
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are...
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health
Tập 3 Số 3 - Trang 291-300 - 2017
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and...
Accelerating drug development for Alzheimer's disease through the use of data standards
Tập 3 - Trang 273-283 - 2017
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for...
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Tập 4 - Trang 444-449 - 2018
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe...
Pregnancy loss and risk of later dementia: A nationwide cohort study, Denmark, 1977–2017
Tập 5 - Trang 146-153 - 2019
AbstractIntroductionPregnancy losses may be associated with increased risks of
dementia.MethodsWe conducted a register‐based cohort study in 1,243,957 women
with ≥1 pregnancy in Denmark in the period 1977–2015. Using Cox regression, we
estimated hazard ratios (HRs) comparing risks of dementia in women with and
without pregnancy losses.ResultsDuring 21,672,433 person‐years of follow‐up,
261,279 wom...
A 24‐week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease
Tập 1 - Trang 131-140 - 2015
AbstractBackgroundThe lipoprotein‐associated phospholipase A2 inhibitor
(Lp‐PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to
slow the progression of Alzheimer's disease (AD).MethodsOne hundred twenty‐four
subjects with possible mild AD and with neuroimaging evidence of cerebrovascular
disease were randomized to placebo or 250‐mg rilapladib once daily, for
24 weeks, in a...
Design of the ExCersion‐VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment
Tập 3 - Trang 157-165 - 2017
AbstractThere is evidence for a beneficial effect of aerobic exercise on
cognition, but underlying mechanisms are unclear. In this study, we test the
hypothesis that aerobic exercise increases cerebral blood flow (CBF) in patients
with vascular cognitive impairment (VCI). This study is a multicenter
single‐blind randomized controlled trial among 80 patients with VCI. Most
important inclusion crite...
Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested
Tập 4 - Trang 54-63 - 2018
AbstractIntroductionPhotobiomodulation was assessed as a novel treatment of
Alzheimer's disease (AD) by the use of a new device RGn500 combining photonic
and magnetic emissions in a mouse model of AD.MethodsFollowing the injection of
amyloid β 25‐35 peptide in male Swiss mice, RGn500 was applied once a day for 7
days either on the top of the head or the center of abdomen or
both.ResultsRGn500 dail...